Targeted alpha therapy for glioblastoma

According to the World Health Organization 2021 classification of central nervous system tumours, glioblastoma (GB) is a primary brain tumour and presents with the worst prognosis. Because of its infiltrating character, molecular heterogeneity, and only partly preserved function of the blood-brain barrier the median overall survival time is short (9-15 months), regardless of comprehensive treatment including surgery, radio- and chemotherapy. Several novel treatment strategies are under investigation. Unfortunately, none of them with successful results; 90% of patients have recurrence of disease within 6 months. Local administration of drug could be a promising approach to deliver treatment with minimized side effects, as 95% of glioblastomas evince themselves as unifocal lesion recuring within a 2-cm margin at the primary site. Several ligand-receptor systems have been evaluated like targeting tenascin, the extracellular matrix protein, or radiolabelled somatostatin analogues as it is overexpressed with the SSTR-2 receptor system in about 80% of gliomas. Moreover, the study revealed that the NK-1 receptor is overexpressed in GB, so the substance P (SP) can be used as a ligand. A variety of radioisotopes with different physical properties– beta- (131I, 90Y, or 177 Lu), as well as alpha emitters (213Bi, 225Ac or 211At) were tested for treatment.

KUNIKOWSKA Jolanta;  MORGENSTERN Alfred;  PELKA Kacper;  BRUCHERTSEIFER Frank;  KROLICKI Leszek; 

2023-01-12

FRONTIERS MEDIA SA

JRC132316

2296-858X (online),   

https://www.frontiersin.org/articles/10.3389/fmed.2022.1085245/full,    https://publications.jrc.ec.europa.eu/repository/handle/JRC132316,   

10.3389/fmed.2022.1085245 (online),